Evotec SE (NYSE: EVO) — Perfil da empresa, notícias e dados financeiros
Evotec SE is a biotechnology company engaged in drug discovery and development, partnering with pharma to address unmet medical needs.
Evotec SE
Evotec (ETR:EVT), (NASDAQ:EVO) is a biotechnology company dedicated to drug discovery and development services. It engages in partnerships with pharma and biotech for drug discovery, leverages a broad range of therapeutic areas, and offers a suite of technology platforms to progress its projects from research through to commercialization. With a focus on innovation in drug discovery, Evotec aims to develop novel therapeutic options for diseases with unmet medical needs. Its operations span from early-stage discovery to pre-clinical development, incorporating a variety of projects across different therapeutic areas including neuroscience, diabetes, oncology, and infectious diseases, among others. Evotec's objective is to create value by accelerating the drug development process, reducing costs for its partners, and ultimately delivering more effective treatments to improve patient outcomes.
Resumo
Operações
Produtos e/ou serviços de Evotec SE
- Drug discovery and development services: Offers end-to-end integrated drug discovery and development services, leveraging advanced technologies like AI.
- Just - Evotec Biologics: Provides integrated design, development, and manufacturing services for biologics, focusing on efficiency and cost-effectiveness.
- Bridging the innovation gap: Collaborates with academic, biotech, and pharmaceutical partners to transform early-stage research into drug discovery projects.
- EVOcells: Focuses on cell therapy projects, including the development of iPSC-based therapies, aiming to treat serious diseases.
- Target-to-Clinic Platform: Accelerates drug discovery through a comprehensive suite of capabilities from target identification to clinical entry.
- BEOncology: Dedicated to discovering and developing new cancer therapies using a broad range of cutting-edge technologies.
equipe executiva do Evotec SE
- Christian WojczewskiCEO & Chairperson of the Management Board
- Aurelie DalbiezChief People Officer & Member of Management Board
- Claire HinshelwoodCFO & Member of Management Board
- Ingrid MllerCOO & Member of Management Board
- Sarah FakihExecutive VP, Head of Global Communications & Investor Relations
- Christian DargelEVP Global Head of Legal & Compliance
- Ian M. HunneyballSenior Vice President of Programme Management & Clinical Operations
- David HalletExecutive Vice President
- Uwe AndagEVP Head of Metabolic Diseases
- Christiane HonischSVP Head of Diagnostics
Últimas notícias sobre a Evotec SE
Evotec CSO Cord Dohrmann steps down
United StatesEvotec starts Phase 1 antibody trial
United StatesEvotec partners on tumor therapy research
United StatesEvotec signs AI drug discovery partnership
United StatesEvotec targets 18-month J.TRAIN biologics deployments
United StatesEvotec and Almirall fast-track dermatology candidate to preclinical development
United States
Principais indicadores financeiros
Resultados divulgados pela Evotec SE , em EUR.
- Cap. de mercado
- 558 mi
- Receita (TTM)
- 717,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- -27.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 757,3 mi | -135,3 mi | -99,4 mi | |
| 797 mi | -142,5 mi | -196,1 mi | |
| 781,4 mi | -107,1 mi | -83,9 mi | |
| 751,4 mi | 20,9 mi | -175,7 mi |